Meniere disease
Drug research and approvals for meniere disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 6 studies of meniere disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With PhenotypesNCT07518069 · Not reported · IRCCS San Raffaele · starts Apr 9, 2025
- Sleep Disorders and Their Impact on Patients With Ménière's DiseaseNCT07299578 · Not reported · University Hospital, Strasbourg, France · starts Jul 19, 2024
- The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo…NCT05851508 · Phase 3 · Leiden University Medical Center · starts Oct 1, 2023
- Treatment of Meniere's Disease With Migraine MedicationsNCT05582837 · Phase 4 · University of California, Irvine · starts Aug 1, 2022
- Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel…NCT04806282 · Not reported · National Institute on Deafness and Other Communication Disorders (NIDCD) · starts Aug 17, 2021
- Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear…NCT03587701 · Phase 2 · Andrea Vambutas · starts Jan 3, 2019
Phase 3 3
- DexamethasoneGlucocorticoid receptor agonist
- EbselenAntioxidant
- FamciclovirHuman herpesvirus 1 DNA polymerase inhibitor
Phase 2 5
- GentamicinBacterial 70S ribosome inhibitor
- VenlafaxineSerotonin transporter inhibitor
- AnakinraInterleukin-1 receptor antagonist
- LatanoprostProstanoid FP receptor agonist
- AcyclovirHuman herpesvirus 1 DNA polymerase inhibitor
Phase 1 or earlier 1
- BetahistineHistamine H3 receptor antagonist
How its trials ended
70 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 15 whose ending is known, 20% met their primary endpoint, 7% missed it and 73% stopped early.
- Completed, result not reported2941%
- Ongoing1623%
- Status unknown1014%
- Stopped: other or unclear57%
- Stopped: lack of efficacy46%
- Met its primary endpoint34%
- Missed its primary endpoint11%
- Stopped: enrollment or feasibility11%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA